What the NICE Guidelines Say About Mounjaro for Type 2 Diabetes

Step 1: Understand which NICE appraisal applies to your situation

NICE has produced more than one piece of guidance touching tirzepatide. For people with type 2 diabetes, the relevant appraisal is the diabetes-specific technology appraisal, which sets out criteria around HbA1c targets, current treatment regimen, and body weight. For weight management, NICE TA1026 (published December 2024, updated September 2025) recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, including type 2 diabetes. You can read the full recommendations on the NICE TA1026 guidance page.

In practice, a person living with type 2 diabetes might be eligible under the diabetes pathway, the weight-management pathway, or both. The one that applies to you depends on whether your GP is treating your diabetes primarily, whether you've been referred to a specialist weight management service, and what your current medication history looks like. These are clinical judgements, not administrative ones. If you're unsure which route fits your situation, the right first step is a conversation with your diabetes team or GP.

What the two appraisals share is the underlying medicine: tirzepatide, the dual GIP and GLP-1 receptor agonist made by Eli Lilly. The NHS tirzepatide page has a clear plain-English summary of how it works and what it's used for, which is worth reading alongside any guidance document.

Step 2: Know what the diabetes pathway actually requires

Under the diabetes-specific NICE appraisal, tirzepatide is recommended as an add-on treatment when blood glucose remains insufficiently controlled despite existing medication. The guidance specifies minimum HbA1c thresholds and sets expectations around what other treatments should already have been tried. BMI is also part of the picture: the diabetes appraisal includes BMI criteria, and lower BMI thresholds apply for people of South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, in line with broader UK clinical guidance. For full eligibility detail specific to the diabetes appraisal, the Mounjaro NICE guidelines and diabetes page covers this in depth.

Commissioning on the NHS also depends on your local Integrated Care Board. Even where NICE recommends a treatment, access is not always immediate or uniform across England. Scotland, Wales, and Northern Ireland use their own assessment processes, so eligibility criteria can differ depending on where you live.

If you are already using tirzepatide for weight management and also have type 2 diabetes, the clinical conversation about which indication your prescription sits under is worth having explicitly with your prescriber. The medicine is the same; the pathway, monitoring expectations, and prescription source may not be.

Step 3: Consider what private treatment looks like for this situation

For people with type 2 diabetes who don't meet current NHS criteria, who don't want to wait, or whose GP practice has not yet joined the new prescribing contract that came into effect from April 2026, a private prescription is the alternative. At nume, a GPhC-registered independent prescriber reads every consultation personally (not a piece of software) before any prescription is issued. That assessment covers your diabetes history, current medications including anything that might interact, and your overall clinical picture.

One thing worth flagging for people with type 2 diabetes specifically: tirzepatide can lower blood glucose significantly. If you're also taking insulin or a sulphonylurea, there is a real risk of hypoglycaemia, and your diabetes medicines may need adjusting when you start. This is not a theoretical concern. Your prescriber and diabetes team need to know about each other's involvement. Ideally, your GP is informed before treatment starts, a step we take as standard, in line with GPhC guidance.

You can find an honest overview of what private treatment involves, including how prescriptions are issued and what to expect on delivery, on the Mounjaro for type 2 diabetes page. If cost is a factor, the Mounjaro pricing page sets out the context plainly. The consultation itself is free, and if you'd like to check whether you're likely to be suitable before going further, you can do that without committing to anything.

What's still uncertain, and who to speak to

There are genuine areas of uncertainty when tirzepatide is used alongside complex diabetes regimens. Long-term effects beyond the trial periods are still being studied; the medicine carries a Black Triangle (▼) from the MHRA, meaning additional monitoring continues. Interaction with certain diabetes medications, the timing of any HbA1c retesting, and how to manage dose titration alongside existing insulin are all questions your clinical team should own. This page cannot answer them for you specifically, and nothing here should be read as personal dosing advice.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. These exclusions apply regardless of the clinical indication. If any of those circumstances apply to you, speak to your GP or specialist before making any decision about treatment. If you have type 1 diabetes, the picture is different again, and the Mounjaro and type 1 diabetes page explains why the considerations there require separate attention.

If you'd like to understand how tirzepatide sits within the broader landscape of GLP-1 and dual-agonist medicines, the Mounjaro overview is a good place to read across the full picture. For questions specific to how the medicine interacts with certain lifestyle factors, the alcohol and Mounjaro page is worth a look, it comes up often enough that our prescribers field it most weeks.

If you have a specific question about your situation, the most useful thing to do is start with a free consultation. A real clinician will look at your history and give you an honest answer. Our contact page has support available seven days a week. You can also check your eligibility now, at no cost.